The industry view on long-term toxicology testing in drug development of human pharmaceuticals.
The approach to chronic toxicity testing over the past decade is reviewed and assessed in the light of developing ICH guidelines. The 1990's have seen a general acceptance that studies with a maximal duration of 6 months in rodents are all that is required for adequate safety assessment of developmental pharmaceutical agents. However, controversy has arisen concerning the most appropriate duration for chronic toxicity testing in non-rodents. Initial suggestions that 6 months duration was sufficient have been countered by findings noted in 12-month studies that were not seen in shorter-term studies. Retrospective analysis of available data eventually lead to a subsequent ICH recommendation that studies of 9 months duration would be now acceptable. However, until recently the FDA position on this recommendation was unclear and an analysis of industry practices since the ICH recommendation was made in 1997 has shown that the 9-month guideline is not widely applied. Recent clarification by the FDA will probably result in a continued but limited use of this alternative. An industry view on the future of chronic toxicology testing in rodents and non-rodents is presented.
Van Cauteren
H
H
Novartis, Basle, Switzerland. herman.van_cauteren@pharma.novartis.com
Bentley
P
P
Bode
G
G
Cordier
A
A
Coussement
W
W
Heining
P
P
Sims
J
J
D000818:Animals; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004345:Drug Industry; D006801:Humans; D012377:Rodentia; D014116:Toxicology; D014481:United States; D014486:United States Food and Drug Administration